Documente Academic
Documente Profesional
Documente Cultură
* These data are from the 2005 Monitoring the Future survey, funded by the National Institute on Drug Abuse,
National Institutes of Health, DHHS, and conducted annually by the University of Michigan’s Institute for Social
Research. The survey has tracked 12th-graders’ illicit drug use and related attitudes since 1975; in 1991, 8th- and
10th-graders were added to the study. The latest data are online at www.drugabuse.gov.
** “Lifetime” refers to use at least once during a respondent’s lifetime. “Annual” refers to use at least once during the
year preceding an individual’s response to the survey. “30-day” refers to use at least once during the 30 days preced-
ing an individual’s response to the survey.
*** NSDUH (formerly known as the National Household Survey on Drug Abuse) is an annual survey of Americans
age 12 and older conducted by the Substance Abuse and Mental Health Services Administration. Copies of the latest
survey are available at www.samhsa.gov and from the National Clearinghouse for Alcohol and Drug Information at
800-729-6686.
References
1
Volkow, N.D., Fowler, J.S., Wang, G., Ding, Y., and Gatley, S.J. (2002). Mechanism of action of methylphenidate:
insights from PET imaging studies. J. Atten. Disord., 6 Suppl. 1, S31–S43.
2
Konrad, K., Gunther, T., Hanisch, C., and Herpertz-Dahlmann, B. (2004). Differential Effects of Methylphenidate on
Attentional Functions in Children With Attention-Deficit/Hyperactivity Disorder. J. Am. Acad. Child Adolesc. Psychiatry,
43, 191–198.
3
Faraone, S.V., Spencer, T., Aleardi, M., Pagano, C., and Biederman, J. (2004). Meta-analysis of the efficacy of
methylphenidate for treating adult attention-deficit/hyperactivity disorder. J. Clin. Psychopharmacology, 24, 24–29.
4
Kutcher, S., Aman, M., Brooks, S.J., Buitelaar, J., van Daalen, E., Fegert, J., et al. (2004). International consensus
statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): Clinical impli-
cations and treatment practice suggestions. Eur. Neuropsychopharmacol., 14, 11–28.
5
Biederman, J. (2003). Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for
substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. J. Clin. Psychiatry, 64
Suppl. 11, 3–8.
6
Wilens, T.E., Faraone, S.V., Biederman, J., and Gunawardene, S. (2003). Does stimulant therapy of attention-
deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics, 111,
179–185.